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Summary: The analytical performance of a direct, immunoseparation based LDL-cholesterol method (Genzyme
Corporation) was evaluated on an ELAN analyser (Merck), and compared with the performance of routinely used
methods (LDL-cholesterol estimated by the Friedewald equation, and LDL-cholesterol obtained after polyvinyl
sulphate precipitation). Within-day coefficients of variation (CVs) were 0.79 to 2.51% for immunoseparation based
LDL-cholesterol; the between-day CVs varied between 2.62 and 3.89%, i.e. within the recommended National
Cholesterol Education Program (NCEP) goal of < 4%. A method comparison study, according to the National
Committee for Clinical Laboratory Standards (NCCLS) EP9-P guidelines, was performed using fasting normo- and
hypertriacylglycerolaemic as well as cholestatic sera. In fresh normotriacylglycerolaemic sera immunoseparation
based LDL-cholesterol (y) and Friedewald LDL-cholesterol (x) values were identical as slope and intercept of the
Passing & Bablok regression equation were not significantly different from one and zero, respectively (y = 1.006 χ
— 0.107; Ν = 45). In contrast, immunoseparation based LDL-cholesterol (y) differed significantly from polyvinyl
sulphate LDL-cholesterol (x) results (y = 0.922 χ + 0.234; Ν = 103). Freezing normotriacylglycerolaemic sera
(three weeks, —20 °C) resulted in a negative bias of —5.8% for the immunoseparation based LDL-cholesterol
method, and in a positive bias of + 5.3% for the polyvinyl sulphate method, compared to fresh specimens. Immuno-
separated LDL-cholesterol was completely recovered up to at least 37.84 mmol/1 serum triacylglycerols.
We conclude that the immunoseparation based LDL-cholesterol method is a practical, not technically demanding
technique well applicable within routine clinical laboratories. The method shows a markedly improved analytical
precision in comparison to current routine methods, and hence has potential to decrease total test imprecision. The
immunoseparation based LDL-cholesterol method produces results identical to those obtained by Friedewald in
healthy blood donors, and above all overcomes a major pitfall of the Friedewald equation enabling LDL-cholesterol
measurements in hypertriacylglycerolaemic sera. Its acceptance should improve the reliability of LDL-cholesterol
testing and improve clinical decision making.
Introduction
Serum LDL-cholesterol is an important risk factor for nary Primary Prevention Trial it was concluded that each
coronary heart disease (1-^2). Intervention trials have 1% reduction in serum LDL-cholesterol level decreased
demonstrated that lowering (LDL)cholesterol either by the incidence of coronary heart disease risk by 2%. Be-
diet or drug therapy decreased the incidence of coronary cause of the strong, positive link between LDL-choles-
heart disease (3). From the Lipid Research Clinics Coro- terol and coronary heart disease, both the European
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Atherosclerosis Society (4) as well as the Children and
Adolescent Treatment Panel, and the Adult Treatment
Panel (5-6) of the US National Cholesterol Education
Program (NCEP) made LDL-cholesterol the focal point
of classification of therapy, and stressed the importance
of setting individual goal values for LDL-cholesterol.
Consequently, LDL-cholesterol assays play a central
role in the evaluation and management of hypercholest-
erolaemia.
Yet, measuring cholesterol in LDL is considerably more
complicated than measuring total cholesterol, the latter
not being influenced by the method of lipoprotein sepa-
ration, or by cholesterol transfer between lipoproteins.
For total cholesterol a Definitive Isotope Dilution/Mass
Spectrometry Method and a Reference Abell-Kendall
Method have been established to evaluate the accuracy
of cholesterol analyses (7-8). For LDL-cholesterol no
such formal standardization among lipoprotein laborato-
ries exists.
In this study the analytical performance of a direct im-
munoseparation based LDL-cholesterol assay (9) was
evaluated and compared with methods currently used in
European routine clinical laboratories. The comparison
methods were: LDL-cholesterol estimated according to
Friedewald (10), and LDL-cholesterol obtained indi-
rectly after polyvinyl sulphate precipitation of LDL and
enzymatic determination of non-LDL-cholesterol in the
supernatant. In the latter method LDL-cholesterol is cal-
culated as the difference between total cholesterol, de-
termined in neat serum, and cholesterol in the polyvinyl
sulphate supernatant (11 — 13). The aims of this evalua-
tion study were fivefold: firstly, to apply the immuno-
separation based LDL-cholesterol method to an auto-
mated clinical chemistry analyser so that the analytical
variability is improved compared to current methods; se-
condly, to document the analytical variability for all
three LDL-cholesterol methods, and to verify for which
methods the recommended NCEP goal of 4% CV for
LDL-cholesterol measurements could be reached (14);
thirdly, to set up an LDL-cholesterol method comparison
study in fresh fasting sera from selected healthy and dis-
eased individuals — hypertriacylglycerolaemic and cho-
lestatic patients - in order to document comparability
with current routine methods and to check whether tri-
acylglycerols and lipoprotein-X (Lp-X) affect the immu-
noseparation based LDL-cholesterol assay. Fourthly, to
document the effect of freezing on immunoseparation
based LDL-cholesterol. Finally, to evaluate indirectly
the specificity of the immunoseparation step by check-
ing the correlation between filtrate LDL-cholesterol and
serum apolipoprotein B, between filtrate apolipoprotein
B and serum apolipoprotein B, and between filtrate lipo-
protein(a) (Lp(a)) and serum Lp(a).
Materials and Methods
Patient sera
Fasting sera were obtained over a four month period by venipunc-
ture from
1: apparently healthy normotriacylglycerolaemic blood donors
(N = 103: 58 in the pilot study, 45 in the final study),
2: patients from the lipid clinic with known hypertriacylglycero-
laemia or hospitalized patients with visually turbid sera due to ele-
vated serum triacylglycerols (N = 30), and
3: hospitalized patients with cholestasis (N = 12). In the chole-
static group five patients suffered from cirrhosis of the liver, five
from acute hepatitis and two from obstructive jaundice.
Mean bilirubin, alkaline phosphatase1) and γ-glutamyltransferase1)
levels were 124 μηιοΐ/ΐ, 175 U/l and 200 U/l respectively. Mini-
mum-maximum ranges were 21—371 μπιοΐ/l, 78-430 U/l and
48—664 U/l, the respective corresponding upper reference limits
being 14 μπκ>1/1, 75 U/l and 35 U/I.
Venous blood was drawn into vacuum tubes (Becton Dickenson).
Plain tubes were left to clot for at least 30 minutes and centrifuged
to obtain serum. For the method comparison study duplicate immu-
noseparation based LDL-cholesterol, polyvinyl sulphate LDL-cho-
lesterol and total cholesterol analyses were performed the same
day in fresh sera. Forty-five normotriacylglycerolaemic sera were
aliquoted and stored frozen at —20 °C during three weeks. Dupli-
cate immunoseparation based LDL-cholesterol and polyvinyl sul-
phate LDL-cholesterol determinations were repeated on frozen ali-
quots and compared to fresh LDL-cholesterol results. HDL-choles-
terol, triacylglycerols, apolipoprotein B and Lp(a) measurements
were all performed on frozen serum aliquots.
Methods
LDL-cholesterol immunoseparation reagent
The LDL-cholesterol Immunoseparation reagent (Cat. No. 2461-
03, Genzyme Corporation, Cambridge, MA, USA) utilizes latex
beads coated with immunoaffmity chromatography purified poly^
clonal goat antibodies to human apolipoproteins A-I and E. The
antibodies are bound to separate populations of polystyrene latex
beads, that are combined in a somewhat viscous reagent suspen^
sion. The antibody-coated beads selectively remove chyiomicrons,
HDL, IDL and VLDL lipoproteins from serum, while LDL and
Lp(a) remain in the filtrate (Genzyme product information). A
dual-chamber microcentrifuge filter unit consisting of a smaller in-
ner tube equipped with filter, and a larger outer housing with cap,
separates the HDL and VLDL-loaded beads from unbound LDL in
the filtrate. The lot number of the reagent kits evaluated was
D3316A.
Procedure used for the immunoseparation based LDL-cholesterol
determinations
Pipette 200 μΐ of reagent into the dual-chamber microcentrifuge
filter unit. Add 30 μΐ of patient serum. Cap the device and mix
immediately by vortexing. Do not mix by inversion. Incubate for
') Enzymes:
Cholesterol oxid se; cholesterol : oxygen oxidoreductase, EC
1.1.3.4
Glycero-phosphate oxidase; I-glycerol-3-phosphate : oxygen oxi-
doreductase, EC 1.1.3.21
γ-Glutamyltransferase; (y-glutamyl)-peptide : amino acid γ-gluta-
myl transferase, EC 2.3.2.2
Alkaline phosphatase; orthophosphoric monoester phosphohydro-
lase, EC 3.1.3.1
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10 minutes at room temperature. Centrifuge at room temperature
for 5 minutes at 12000g. Remove and discard the inner tube. As-
say the filtrate collected in the outer tube using a cholesterol assay.
Correct the results for dilution of the sample with LDL reagent, by
means of a batch-specific multiplication factor provided by Gen-
zyme. The LDL immunoseparation reagent batch number used in
this evaluation study was 3197B, the corresponding multiplication
factor was 7.35.
LDL filtrates were analysed for cholesterol on an ELAN analyser
(Merck, Darmstadt, Germany) using an application for low-level
cholesterol measurements and an enzymatic cholesterol-oxidase1)/
phenol-aminophenazone (CHOD-PAP) method (Monotest Choles-
terol High Performance, Cat. No. 236691, Boehringer, Mannheim,
Germany). Frozen human serum which was targeted with the cho-
lesterol Abell-Kendall Reference Method (15) - quadruplicate
analyses in four runs - was used as calibrator.
Quality control materials
Genzyme human control sera were used to assess the within-day
and day-to-day reproducibility for the immunoseparation based
LDL-cholesterol method. The Genzyme controls investigated were
direct LDL Cholesterol Desirable Level Control, and Risk Level
Control (batch nr. D3298B with a target mean of 2.39 mmol/1, and
bath nr. D3025A with a target mean of 5.29 mmol/1).
Precinorm® (Cat. No. 781827, Lot No. 180033, Boehringer Mann-
heim) and/or Seronorm® (Cat. No. 65, Lot No. 65, Nycomed) were
used for daily quality control of cholesterol, HDL-cholesterol and
polyvinyl sulphate LDL-cholesterol determinations, while for tria-
cylglycerols Testpoint™ 1 (Unassayed Chemistry Control 1,
NORM, Technicon, Cat. No. T13-1070, Lot No. V09316) and Test-
point™ 2 (Unassayed Chemistry Control 2, ABN, Technicon, Cat.
No. T13-1071, Lot no. V093170) were used.
LDL-cholesterol comparison methods
Precipitation method: Polyvinyl sulphate LDL-cholesterol deter-
minations were performed on supernatants after LDL precipitation
from serum by polyvinyl sulphate, in the presence of EDTA and
polyethylene glycol methyl ether (Cat. Nr. 726290, Boehringer,
Mannheim, Germany), using Boehringer CHOD-PAP reagent (Mo-
notest Cholesterol High Performance, Cat. No. 236691, Boeh-
ringer, Mannheim, Germany) on a semi-automated system. Polyvi-
nyl sulphate LDL-cholesterol was calculated as the difference be-
tween total cholesterol, and cholesterol in the polyvinyl sulphate
supernatant. Therefore, the polyvinyl sulphate method is an indirect
LDL-cholesterol method. A Preciset® Cholesterol standard of 5.17
mmol/1 was used for calibration (Cat. Nr. 125512, Boehringer,
Mannheim, Germany).
Estimated LDL-cholesterol: LDL-cholesterol was estimated as
LDL-cholesterol = total cholesterol — HDL-cholesterol — (triacyl-
glycerols/2.2), according to the original Friedewald formula (10).
Cholesterol, LDL-cholesterol, HDL-cholesterol and triacylglycerol
values are all expressed in mmol/1. In this study LDL-cholesterol
could only be estimated in the blood donor group, because of docu-
mented limitations (10, 16).
Total and HDL-cholesterol determinations were carried out with a
semi-automated procedure using Boehringer CHOD-PAP reagent
(Monotest Cholesterol High Performance, Cat. No. 236691, Boeh-
ringer, Mannheim, Germany). HDL-cholesterol was measured in
the supernatant after phosphotungstic acid/MgCl2 precipitation of
non-HDL particles (Cat. No. 14210, Merck, Darmstadt, Germany).
Preciset® Cholesterol standards of 1.29 and 5.17 mmol/1 were used
for calibrating the HDL-cholesterol and total cholesterol assays,
respectively (Cat. Nr. 125512, Boehringer, Mannheim, Germany).
The laboratory which performed the lipid analyses maintains total
and HDL-cholesterol standardization through the Lipid Standard-
ization Panel of the Centers for Disease Control (CDC) -- National
Heart Lung and Blood Institute. The laboratory is also a member of
the Cholesterol Reference Method Laboratory Network (CRMLN)
established by CDC (17).
Serum triacylglycerols without glycerol blanking were determined
on a Chem 1 analyser (Technicon Inc., Tarrytpwn, New York,
USA) using the UV method of Bucolo & David (Technicon, Cat.
No. T01-1656-53, method No. SA4-0324L90).
Apolipoprotein B was determined on a Beckman Array with Beck-
man calibrator (Cat, Nr. 449370) and reagent (Cat. Nr. 449310)
both in LDL filtrates and in neat serum, filtrates being diluted 6-
fold instead of 36-fold.
Lipoprotein(a) (Lp(a)) was measured in neat serum and LDL
filtrates using TintElize Lp(a) (Cat. Nr. 610220, Biopool, Umea,
Sweden), filtrates being diluted 357-fold instead of 2601-fold. Re-
sults were expressed in mg/l Lp(a) mass.
Method comparison study
The LDL-cholesterol comparison was performed essentially ac-
cording to the NCCLS EP9-P protocol (18). The lipid distributions
of the specimens tested in the final study were: 3.57-8.10 mmol/1
for cholesterol, 1.58-5.98 mmol/1 for polyvinyl sulphate LDL-
cholesterol, and 0.57-2.81 mmol/1 for triacylglycerols in the blood
donor subgroup; 3.65-15.47 mmol/1 and 2.26-37.76 mmol/1
respectively for cholesterol and triacylglycerols in the hypertriacyl-
glycerolaemic group; and 1.94-11.88 mmol/1 and 0.54-22.71
mmol/1 respectively for cholesterol and triacylglycerols in the cho-
lestatic group.
A comparison between all three LDL-cholesterol methods could
only be performed in the normotriacylglycerolaemic patients
(N 45) (10, 16). Immunoseparation and polyvinyl sulphate de-
rived LDL-cholesterol results were compared within the hypertri-
acylglycerolaemic and cholestatic patient groups.
Triacylglycerol interference test
A dilution series was prepared by mixing a high and a low triacyl-
glycerol serum pool. The triacylglycerol range tested varied be-
tween 1.51 and 37.84 mmol/1. Immunoseparation and polyvinyl
sulphate derived LDL-cholesterol determinations were performed.
LDL-cholesterol recovery was assessed by means of linear regres-
sion analysis (x: % high pool, y: measured LDL-cholesterol).
Statistical analysis
Comparability of LDL-cholesterol methods was assessed by
Bablok & Passing regression analysis (19). A significance level of
α = 0.05 was adopted.
Results
1. Direct LDL-cholesterol application
on ELAN
The ELAN analyser is an open system enabling free pro-
gramming of nearly all parameter settings. As approxi-
mately 7-fold sample predilutions are made with the di-
rect LDL-cholesterol immunoseparation reagent, a
filtrate : reagent volume ratio of 25 μΐ : 250 μΐ was pro-
grammed to ensure adequate analytical sensitivity.
As the ELAN pipetting system was found to be matrix
sensitive, a fresh frozen human serum cholesterol cali-
brator was used. Moreover, it was also necessary to di-
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lute the cholesterol calibrator like the LDL-cholesterol
filtrates: before each run the calibrator was thawed and
diluted 7.35-fold with physiological saline solution.
Using this procedure matrix problems could be avoided.
A mean absorbance of 0.4655 was measured at a 5.28
mmol/1 serum cholesterol concentration level, resulting
in a sensitivity of ΔΑ = 0.088 per mmol I"1 LDL-cho-
lesterol. The calibrator factor obtained was 11.232, with
a CV over the four month evaluation period of 1.50%
(N = 23).
2. Wi th in- run precision
For the Desirable Level Control the CVs were 1.36, 2.51
and 2.38% over three consecutive days. For the Risk
Level Control the CVs were 0.79, 1.17 and 1.44%. The
within-run mean values were 2.48, 2.57 and 2.43 mmol/1
respectively for the desirable level, and 5.46, 5.49 and
5.35 mmol/1 for the risk level. These within-run mean
values represent twenty-one LDL immunoseparations
analysed in a single run and repeated on three consecu-
tive days. N
3. Between-day precision
Mean analytical variability for respectively total choles-
terol, triacylglycerols and HDL-cholesterol over the
evaluation period was 0.86%, 2.09% and 4.17%. Conse-
quently, the calculated analytical variability of Friede-
wald LDL-cholesterol was 4.74%. For polyvinyl sul-
phate LDL-cholesterol the between-day imprecision
over a four month period (N = 23) was 5.64% at 2.74
mmol/1. For immunoseparation based LDL-cholesterol
the between-day CV over the same period (N = 24) was
3.89% at 2.43 mmol/1 and 2.64% at 5.37 mmol/1, result-
ing in a mean CV of 3.27%.
4. Method comparison of immunoseparation
based LDL-cholesterol with Friedewald
LDL-cholesterol and polyvinyl sulphate
LDL-cholesterol
The Passing & Bablok regression equations are pre-
sented in table 1. No outliers were present. In fresh nor-
motriacylglycerolaemic sera slope and intercept for im-
munoseparation based LDL-cholesterol versus Friede-
wald LDL-cholesterol did not differ significantly from
one and zero, respectively. In contrast, immunosepara-
tion based LDL-cholesterol differed significantly from
polyvinyl sulphate LDL-cholesterol. In hypertriacyl-
glycerolaemic sera Friedewald LDL-cholesterol could
not be estimated (10). A weak correlation existed be-
tween immunoseparation based LDL-cholesterol and
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as a 20% mean difference (polyvinyl sulphate LDL-cho-
lesterol: 2.91 mmol/1; immunoseparation based LDL-
cholesterol: 3.62 mmol/i), suggesting a different triacyl-
glycerol effect on one or either LDL-cholesterol method.
After immunoseparation none of the LDL filtrates
looked turbid, while after polyvinyl sulphate precipita-
tion nearly half of the supernatants remained turbid or
non-homogeneous. Eliminating turbid polyvinyl sul-
phate supernatants from the method comparison im-
proved the correlation (r = 0.902). In cholestatic pa-
tients Friedewald LDL-cholesterol could not be esti-
mated because of the abnormal lipoprotein spectrum
(16). The method comparison between immunosepara-
tion based LDL-cholesterol and polyvinyl sulphate
LDL-cholesterol showed somewhat scattered LDL-cho-
lesterol results (r = 0.918).
Freezing samples reduced the immunoseparation based
LDL-cholesterol mean from 3.41 mmol/1 in fresh sera to
3.20 mmol/1 in frozen sera (mean bias = -6.2%, slope
= 0.942). Freezing increased the polyvinyl sulphate
LDL-cholesterol mean from 3.50 mmol/1 in fresh sam-
ples to 3.63 mmol/1 in frozen samples (mean bias
= + 3.7%, slope = 1.053).
5. Triacylglycerol interference
Linear regression analysis on the triacylglycerol dilution
series showed that the immunoseparation based LDL-
cholesterol method maintained linearity (r = —0.998)
and did not suffer from triacylglycerol interference up
to a level of 37.84 mmol/1, in contrast with the polyvinyl
sulphate LDL-cholesterol method. Mean LDL-choles-
terol recovery in the dilution series was 99.5% with the
immunoseparation based method.
6. Specificity of the LDL immunoseparation
step
A correlation coefficient of r ?= 0.970 was found in the
blood donor subgroup when comparing filtrate LDL-
cholesterol with serum apolipoprotein B, compared to
r = 0.965 for polyvinyl sulphate LDL-cholesterol versus
serum apolipoprotein B. The regression equation des-
cribing the relationship between the filtrate and serum
apolipoprotein B was: y = -0.069 + 0.921 χ
(r =5= 0.983). The Passing & Bablok equation describing
the relationship between the filtrate and serum Lp(a)
was: y = -3.871 + 0.755 χ (r = 0.981).
Discussion
LDL-cholesterol has been shown to be a major risk
factor for coronary heart disease in clinical and observa-
tional epidemiological studies (1—3). Hence, determina-
tion of LDL-cholesterol is an essential part in the eval-
uation of dyslipidaemia, coronary heart disease risk clas-
sification and clinical management in individual pa-
tients. Reliable LDL-cholesterol measurements are
particularly important because of the strong correlation
between LDL-cholesterol and coronary heart disease
risk, and because the expected effect of therapy may be
relatively small (diet modification: 10 to 15% reduction;
drug therapy: 15 to > 30% reduction). To detect these
small, yet clinically important differences the total LDL-
cholesterol imprecision should be less than half of the
expected response, i. e. < 5% (20). Current LDL-choles-
terol methods have a total variability of about 8 to 11%
(20—21). Generally, efforts to decrease total variability
involve reducing either analytical and/or biological vari-
ability.
Up to now, LDL-cholesterol was usually estimated by
use of the Friedewald equation (10), which assumes that
the amount of VLDL-cholesterol (in mmol/1) can be es-
timated by dividing the fasting serum triacylglycerol
concentration by a factor of 2.2. Comparison of Friede-
wald LDL-cholesterol with ultracentrifugally obtained
LDL-cholesterol yielded good correlations (r = 0.94 to
0.99), depending on the patient population (10, 22).
McNamara et al. (23) and Warnick et al. (24) docu-
mented that Friedewald LDL-cholesterol was adequate
for risk classification of coronary heart disease patients
since 84 to 86% and 90% of Friedewald LDL-choles-
terol values were within 10% of ultracentrifugally deter-
mined LDL-cholesterol if serum triacylglycerol levels
were < 2.3 mmol/1. Yet, the Friedewald formula suffers
from well-documented deficiencies: it can only be used
in fasting sera; it is inaccurate in case of dysbetalipopro-
teinaemia, when triacylglycerol levels are greater than
4.52 mmol/1, and in diseased patients who have altered
concentrations and composition of lipoproteins (16).
Also, the reliability of Friedewald LDL-cholesterol de-
pends on the accurate measurement of total cholesterol,
HDL-cholesterol and triacylglycerols. Poor precision in
one or all of these measurements will contribute to the
LDL-cholesterol analytical variability (20-21, 25-26).
Ultimately, the biological variability in each of these
three measurements will also contribute to the total vari-
ability of the LDL-cholesterol value (20-21, 25-26).
In an attempt to overcome the limitations of the Friede-
wald formula, indirect polyanion precipitation methods
for LDL-cholesterol were developed (11 — 13). The accu-
racy of these precipitation methods versus ultracentrifu-
gation was reviewed recently (22, 27). From these
studies it was concluded that Friedewald LDL-choles-
terol results agreed better with ultracentrifugation results
than those obtained with precipitation methods. More-
Eur J Clin Chem Clin Biochem 1995; 33 (No 7)
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over, the precipitation methods have shown to be less
accurate and specific, and less -sellable in the case of
hypertriacylglycerolaemia because of co-precipitation of
VLDL with LDL in a concentration-independent way
(27). These findings illustrate the failure of the precipita-
tion methods to overcome major pitfalls of the Friede-
wald formula.
Recently an immunoseparation based direct LDL-cho-
lesterol assay was introduced. We found the method to
be simple and easily applicable on an automated clinical
chemistry analyser. Within-run and between-day im-
precision data for the immunoseparation based LDL-
cholesterol method illustrate that the analytical CV was
improved substantially compared to current routine
LDL-cholesterol methods, and remained below the
NCEP recommended goal of 4% (14). The analytical
imprecision of the immunoseparation based LDL-cho-
lesterol method no longer depends upon the cumulative
analytical variability present in the measurements of tri-
acylglycerols, HDL-cholesterol and total cholesterol (for
estimation of Friedewald LDL-cholesterol), or total and
non-LDL-cholesterol (for calculation of polyvinyl sul-
phate LDL-cholesterol). For the same reason the biologi-
cal variability should also improve. Consequently, the
immunoseparation based method has the potential to re-
duce total test imprecision and to improve clinical deci-
sion making. Further studies to document total test vari-
ability and its impact on coronary heart disease risk clas-
sification are warranted.
The method comparison study (tab. 1) showed that there
was excellent agreement between immunoseparation
based LDL-cholesterol and Friedewald LDL-cholesterol
in normotriacylglycerolaemic sera. Good specificity of
the immunoseparation based LDL-cholesterol method
was to be expected since the reagent contains high-
affinity polyclonal antibodies to human apolipoproteins
A-I and E, separating LDL particles on the basis of their
characteristic apolipoprotein composition. Chylo-
microns contain both apolipoproteins A-I and E, VLDL
and LDL contain apolipoprotein E, HDL contain apoli-
poprotein A-I and sometimes apolipoprotein E. Vesicu-
lar lipoproteins like Lp-X also contain apolipoprotein E
(28, 29). If present, all these particles should be ex-
pected to bind to the latex-coated antibodies. In contrast,
LDL and Lp(a) which do not transport apolipoproteins
A-I and E, are collected in the filtrate, and reported as
'LDL-cholesterol'. In this study we found that Lp(a) was
not completely recovered in the LDL filtrate, the mean
recovery being only 75% (tab. 1). The reason for this
finding is unclear, however matrix effects related to the
Lp(a) assay may have caused the difference. Li et al.
(30) documented that the average overestimation of
Friedewald LDL-cholesterol was 4.1, 8.5 and 21.4% at
Lp(a) concentrations of < 300 mg/1, 301 -600 mg/1 and
> 600 mg/1 respectively. As Friedewald LDL-choles-
terol and polyvinyl sulphate LDL-cholesterol results in-
clude Lp(a)-cholesterol just like the immunoseparation
based LDL-cholesterol method, the method comparison
data produced by either method reflect the same lipopro-
tein classes. Although measurement of Friedewald,
polyvinyl sulphate and immunoseparation based LDL-
cholesterol may be a sensitive and useful gauge of the
sum of these two atherogens, the separation of Lp(a)-
cholesterol from LDL-cholesterol should be made in fu-
ture LDL-cholesterol assays as there is evidence that
LDL and Lp(a) have different prognostic significance
(31).
While the polyvinyl sulphate method and the Friedewald
equation cannot be used in case of even moderate hyper-
triacylglycerolaemia (> 4.52 mmol/1), no triacylglycerol
interference could be documented in the immunosepara-
tion based LDL-cholesterol method up to 37.84 mmol/1,
enabling valid LDL-cholesterol determinations in almost
every hypertriacylglycerolaemic patient, and potentially
in non-fasting subjects. The observation that LDL
filtrates from the triacylglycerol dilution series were
transparent and visually clear after immunoextraction
corroborates the absence of triacylglycerol interference.
When comparing immunoseparation based LDL-choles-
terol versus polyvinyl sulphate LDL-cholesterol slope
and intercept differed significantly from one and zero,
respectively, even in normotriacylglycerolaemic sera.
Fresh sera should be analysed in the immunoseparation
based LDL-cholesterol method since freezing (three
weeks, -20 °C) introduced a significant bias of -5.8%
versus fresh sera.
In cholestasis the presence of Lp-X is likely (16). Al-
though both immunoseparation based LDL-cholesterol
and polyvinyl sulphate LDL-cholesterol do not measure
Lp-X ((22), manufacturers' product information), corre-
lated but scattered LDL-cholesterol results were ob-
tained. We hypothesize that this is probably caused by
different bilirubin interference due to different
sample : reagent ratios in the enzymatic cholesterol as-
says used.
Recently, Me Namara et al. have evaluated 'accuracy'
of the immunoseparation based LDL-cholesterol method
versus the Lipid Research Clinics Beta-Quantification
method (32). The Beta-Quantification method involves
both an ultracentrifugation and a precipitation step.
Briefly, VLDL is removed from neat serum by ultracen-
trifugation at serum density, and LDL' is precipitated
from the infranatant by dextran sulphate-MgCU. VLDL
ultracentrifugation infranatant and LDL precipitation su-
pernatant are measured for cholesterol concentration.
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LDL-cholesterol is determined by the difference be-
tween the VLDL infranatant cholesterol value and the
HDL supernatant cholesterol value (33). Besides its
complexity, the Beta-Quantification method has some
major disadvantages: firstly, the use of a precipitation
method to determine HDL is subject to inaccuracies; se-
condly, LDL values are not measured directly, but are
determined by the difference between VLDL infranatant
and HDL supernatant. Therefore, the reported LDL
value includes other lipoprotein species such as Lp(a)
and IDL. Yet, as large population studies over the last
40 years have reported LDL-cholesterol concentrations
traceable to the Beta-Quantification method, the latter
will presumably become the future Reference Method.
In summary, the immunoseparation based direct LDL-
cholesterol method overcomes major drawbacks of cur-
rent routine LDL-cholesterol methods. Firstly, the de-
creased analytical variability of the direct LDL-choles-
terol method will reduce total test variability, allowing
clinicians to accurately assess coronary heart disease
risk with only one or two blood specimens, and allow a
more reliable assessment of response to diet and drug
therapy. Secondly, the direct LDL-cholesterol method
will also improve biological variability. Thirdly, the di-
rect LDL-cholesterol method produces results identical
to Friedewald, including both LDL- and Lp(a)-choles-
terol. Finally, reliable LDL-cholesterol measurements
can be performed in severe hypertriacylglycerolaemic
samples, and be made with non-fasting specimens. The
high price/test should limit its use to well-considered
requests. We conclude that the immunoseparation based
direct LDL-cholesterol assay is a major improvement
compared to current routine LDL-cholesterol methods.
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